Klinische Studien


KEK

#No.

Insel

#No.

laufende Studien

 

 

Kohorten

246/00

2985

SCCS - Schweizerische Hepatitis C Kohortenstudie mit Hepatitis C Virus Infizierten: Lack of Physical Activity as a Risk Factor for HCC in Patients with chronic Hepatitis C, Analyse von Blutproben gesammelt im Rahmen der SCCSj-Kohortenstudie.

65/10

1898

Kohortenstudie von Patienten mit HCC, ohne Sponsor, keine Medi, kein Blut, nur Fragebögen.

-

-

NABEL Zirrhosen-Datenbak (Kanada und Bern).

143/15

-

Congenital extrahepatic portosystemic shunts (Abernethy malformation): European Survey of current management strategies and clinical outcome.

362/16

3031

Swiss Hepatitis C Cohort Study: Does pregnancy protect against fibrosis or promote SVR in HCV infected women?

922/16

-

SASL 37: Hep B Kohorte.

932/16

-

Pro-Euro DILI Registry - Creation of a Multicentre and Multidisciplinary European Registry of Prospective Drug-Induced Liver Injury Cases (Pro-Euro-DILI).

 

 

Leberkrebs

56/13

2422

BAYER HCC 15982: Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Studie der Phase III zu Regorafenib bei Patienten mit hepatozellulärem Karzinom (HCC) nach Sorafenib.
Link: BAYER HCC 15982

120/13

2412

ARQ 197-A-U303 (METIV-HCC): A phase 3, randomized, double-blind study of Tivantinib (ARQ197) in subjects with MET diagnostic-high inoperable HCC treated with one prior systemic therapy.
Link: METIV - HCC

192/14

2584

BAY 16728: A prospective, single-arm, multicenter, uncontrolled, open-label phase II trial of Refametinib (BAY 86-9766) in combination with Sorafenib as first line treatment in patients with RAS mutant Hepatocellular Carcinoma (HCC.
Link: BAY HCC 16728

071/15

2756

OPTIMIS - „Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib“ (Ergebnisse von HCC-Patienten bei Behandlung mit TACE, entweder gefolgt von Sorafenib oder nicht gefolgt von Sorafenib, und den Einfluss des Zeitpunkts des Behandlungsbeginns mit Sorafenib).

111/15

2961

LILLY (REACH 2) : I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib” (Lilly).

370/15

3034

BMS HCC CA209-040,Nivolumab, phase 3: A Randomized, Multi-Center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma.

213/16

-

Tissue Factor in HCC.

 

 

Virale Hepatitis

125/12

2224

HBV-Genomics: Human Genomics of Fulminant Hepatitis B Infection.

208/13

2488

GS-US-337-0124: A phase 2, multicenter, open-label study to investigate the safety and efficacy of sofosbuvir/ledipasvir fixed-dose combination ribavirin administered in subjects infected with chronic HCV who have advanced liver disease or are post-liver transplant.

090/14

2569

Investigation of the Endocannabinoid System in Hepatitis C Infection.

140/14

2560

Immunpathogenese Hepatitis B.

141/14

2566

A metabolomic and lipidomic investigation in patients with viral hepatitis.

338/14

2755

Abbvie M14-423: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection ((TOPAZ II)).

265/15

2934

Abbvie M13-590: Endurance I, GNT3 Sof/Riba vs ABT493/ABT530 12 weeks, Genotype 1.

321/15

2955

Abbvie M13-594, Endurance 3: A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection.

655/16  

3078

GS-US-342-2104, A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have received a Liver Transplant.

1840/16

3258

Abbvie M15-942 Magellan.

 

 

Metabolische Leberkrankheiten

030/11

2034

NASH EU FLIP Cohort EU-FLIP Cohort of patients with non-alcoholic steatohepatitis.
Homepage: FLIP

063/12

2554

Nashville2, Enquête transversale multicentrique, qui a pour objectif de valider la relation de la signature métagenomique avec ll stade évolutif de la stéatohépatite.

235/12

2307

SASL 34 Treatment of non-alcoholic steatohepatitis (NASH) patients with vitamin D. A randomized, double blind, placebo-controlled multicentre phase II trial in patients with fatty liver disease.
Link: NASH Vitamin D3

324/15

3042

Intercept 747-303 NASH (REGENERATE): A phase 3, double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of obeticholic acid in subjects with nonalcoholic steatohepatitis NASH.

1003/16

 3225

GENFIT: Resolve-it: Genfit GFT505 in NASH phase 3: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of elafibranor in patients with non-alcoholic steatohepatitis NASH and Fibrosis (Emricasan).

1418/16

3263

Conatus IDN-6556-14 A Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension.  (ENCORE-PH).

2129/16

3287

NATIVE: A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH).

1959/16

3293

GS-US-402-1852 NASH: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH).

1542/16

3207

GS-US-416-2124 (A Phase 2, double blind, randomized study evaluating the safety, tolerability and efficacy of GS-4997 in combination with prednisolon versus prednisolon alone in subjects with severe alcoholic hepatitis (AH).

 

 

Zirrhose

073/12

-

PMSR, Sequana Medical AG ALFApump-System Post-Market-Beobachtungsregister - Zur Unterstützung der folgenden Indikation: Automatische Entfernung überschüssiger Peritonealflüssigkeit in die Harnblase bei Patienten mit Zirrhose sowie mit persistenter und refraktärer Aszites, Code: 2011-AAR-004.

038/14

2708

INFECIR-2: Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontenous bacterial peritonitis and high risk of hospital mortality SCNTP880.

076/14

-

Genotypic and Phenotypic Characterisation of Albumin in Cirrhotic Patients.

198/15

2854

Prosper: Phase IV observational hepatic encephalopathy +/- rifaximin.

075 /17

-

SASL 36: The health burden of Primary Biliary Cirrhosis in Switzerland.

741/16

3090

Patients with Liver Cirrhosis: Analysis of the clinical and Radiological Characteristics of Large Spontaneous Portosystemic Shunts and Analysis of Muscle Mass depletion as a Predictor in Morbidity.

 

 

Vaskuläre Lebererkrankung

 213/13

 2492

SASL 35: Swiss Liver Venous Thrombosis Study: A multicenter prospective observational cohort study.

 

 

Andere

366/15

3004

Intercept 747-302 COBALT: A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter
Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis (protocol number 747-302).

 001/16

 2959

Quality Assessment in hepatic hemodynamic procedures at Inselspital: Radiation exposure, iodine contrast use and procedure related complications.

1665/16

3272

SASL 38: Swiss Registry on Autoimmune Hepatitis.

 

3253

SASL 39: Swiss Registry on Primary Biliary Cholangitis.

0148/17

3274

Hemophagocytosis.

 

 

Abgeschlossene Studien

 

 

Liste